International perspectives on screening

Urologic Clinics of North America

Volumn 41, Issue 2, 2014, Pages 237-247

  Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Global; Incidence; Mortality; Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ASIA; AUSTRIA; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; HUMAN; LIFE EXPECTANCY; LITHUANIA; NETHERLANDS; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; UNITED KINGDOM;

GLOBAL; INCIDENCE; MORTALITY; PROSTATE CANCER; PSA; SCREENING;

FORECASTING; HUMANS; INTERNATIONALITY; LIFE EXPECTANCY; MALE; MASS SCREENING; MORBIDITY; PROSTATIC NEOPLASMS; WORLD HEALTH;

EID: 84898025208     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2014.01.009     Document Type: Review

References (57)

1. UN World population prospects: the 2008 revision 2009, United Nations, Department of Economic and Social Affairs, Population Division, New York.
2. Available at: Accessed June 1, 2013. http://publications.cancerresearchuk.org.
3. Alberran J., Hallé N. Hypertrophie et néoplasies épitheliales de la prostate. Ann des Mal. Org. Gen-Urin 1898, 17:797-801.
4. Franks L.M. Latent carcinoma of the prostate. J Pathol Bacteriol 1954, 68:603-616.
5. Available at: Accessed February 13, 2014. http://seer.cancer.gov/statfacts/html/prost.html.
6. Namiki M., Akaza H., Lee S.E., et al. Prostate cancer working group report. Jpn J Clin Oncol 2010, 40(Suppl 1):i70-i75.
7. Akaza H., Hinotsu S., Cooperberg M.R., et al. Sixth joint meeting of J-CaP and CaPSURE-a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol 2013, 43(7):756-766.
8. Kinseth M.A., Jia Z., Rahmatpanah F., et al. Expression between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer 2014, 134(1):81-91.
9. Chu L.W., Ritchey J., Devesa S.S., et al. Prostate cancer incidence rates in Africa. Prostate Cancer 2011, 2011:947870.
10. Stokes W.A., Hendrix L.H., Royce T.J., et al. Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study. Cancer 2013, 119(13):2486-2493.
11. Schröder F.H., Hugosson J., Roobol M.J., ERSPC Investigators, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.
12. Andriole G.L., Crawford E.D., Grubb R.L., PLCO Project Team, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310-1319.
13. Andriole G.L., Crawford E.D., Grubb R.L., PLCO Project Team, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104(2):125-132.
14. Schröder F.H., Hugosson J., Roobol M.J., ERSPC Investigators, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
15. Schröder F.H., Roobol M.J. ERSPC and PLCO prostate cancer screening studies: what are the differences?. Eur Urol 2010, 58(1):46-52.
16. Gulati R., Tsodikov A., Wever E.M., et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012, 23(6):827-835.
17. Ilic D., Neuberger M.M., Djulbegovic M., et al. Screening for prostate cancer. Cochrane Database Syst Rev 2013, (1). CD004720.
18. Djulbegovic M., Beyth R.J., Neuberger M.M., et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010, 341:c4543.
19. Roobol M.J., Carlsson S., Hugosson J. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evid Based Med 2011, 16(1):20-21.
20. Etzioni R., Tsodikov A., Mariotto A., et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008, 19(2):175-181.
21. Etzioni R., Gulati R., Tsodikov A., et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012, 118(23):5955-5963.
22. Etzioni R., Gulati R., Cooperberg M.R., et al. Limitations of basing screening policies on screening trials: the US preventive services task force and prostate cancer screening. Med Care 2013, 51(4):295-300.
23. Gulati R., Gore J.L., Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013, 158(3):145-153.
24. Summaries for patients. Screening smarter, not harder, for prostate cancer. Ann Intern Med 2013, 158(3):1-30.
25. Concato J. Probability, uncertainty, and prostate cancer. Ann Intern Med 2013, 158(3):211-212.
26. Roobol M.J., Carlsson S.V. Risk stratification in prostate cancer screening. Nat Rev Urol 2013, 10(1):38-48.
27. Moyer V.A., U.S.Preventive Services Task Force Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012, 157(2):120-134.
28. Wolf A.M., Wender R.C., Etzioni R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60:70-98.
29. Carter H.B., Albertsen P.C., Barry M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 2013, 190(2):419-426.
30. Heidenreich A., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59:61-71.
31. Kawachi M.H., Bahnson R.R., Barry M., et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010, 8:240-262.
32. Lim L.S., Sherin K. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med 2008, 34:164-170.
33. Murphy D.G., Ahlering T., Catalona W.J., et al. The Melbourne consensus statement on the early detection of prostate cancer. BJU Int 2014, 113(2):186-188.
34. The Committee for Establishment of the Guidelines on Screening for Prostate Cancer, Japanese Urological Association Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol 2010, 17(10):830-838.
35. Available at: Accessed January 10, 2014. http://www.bjuinternational.com/bjui-blog/the-new-aua-psa-testing-guidelines-leave-me-scratching-my-head/.
36. Available at: Accessed January 10, 2014. http://www.siu-urology.org/psa-aid.aspx.
37. Jankevicius F., Adomaitis R., Jievaltas M., et al. The launch of the Lithuanian Early Prostate Cancer Detection Program (EPCDP). Eur Urol Suppl 2007, 6:174.
38. Smailyte G., Aleknaviciene B. Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme. Public Health 2012, 126:1075-1077.
39. Available at: Accessed June 16, 2013. http://controlled-trials.com/ISRCTN84445406.
40. Available at: Accessed June 16, 2013. http://www.cancerscreening.nhs.uk/prostate/index.html.
41. Lane J.A., Hamdy F.C., Martin R.M., et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010, 46(17):3095-3101.
42. Iremashvili V., Soloway M.S., Pelaez L., et al. Comparative validation of nomograms predicting clinically insignificant prostate cancer. Urology 2013, 81(6):1202-1208.
43. Nguyen C.T., Kattan M.W. Formalized prediction of clinically significant prostate cancer: is it possible?. Asian J Androl 2012, 14(3):349-354.
44. Zhu X., Albertsen P.C., Andriole G.L., et al. Risk-based prostate cancer screening. Eur Urol 2012, 61(4):652-661. [review].
45. Kim S.P., Karnes R.J., Nguyen P.L., et al. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol 2013, 189(6):2092-2098.
46. Kranse R., Roobol M., Schroder F.H. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008, 68:1674-1680.
47. Roobol M.J., Steyerberg E.W., Kranse R., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010, 57:79-85.
48. van Vugt H.A., Roobol M.J., Busstra M., et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int 2012, 109(10):1480-1488.
49. van Vugt H.A., Kranse R., Steyerberg E.W., et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer 2012, 48(12):1809-1815.
50. Oberaigner W., Siebert U., Horninger W., et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012, 57(1):57-62.
51. Williams S., Chiong E., Lojanapiwat B., et al. Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol 2013, 14:e524-e534.
52. Gao H.E., Li Y.L., Wu S., et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005, 7(2):159-163.
53. Ito K., Raaijmakers R., Roobol M., et al. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 2005, 103(2):242-250.
54. Ito K., Yamamoto T., Ohi M., et al. Cumulative probability of PSA increase above 4.0 ng/ml in population based screening for prostate cancer. Int J Cancer 2004, 109:455-460.
55. Kobori Y., Kitagawa Y., Mizokami A., et al. Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0 ng/ml as a criterion. Int J Clin Oncol 2008, 13:229-232.
56. Bul M., van Leeuwen P.J., Zhu X., et al. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol 2011, 59:498-505.
57. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate specific antigen level ≤4.0 ng per ml. N Engl J Med 2004, 350:2239-2246.